Medicare Enrolled

Dr. Michael Ip, MD

Ophthalmology · Pasadena, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Consulting-driven
625 S FAIR OAKS AVE STE 280, Pasadena, CA 91105
6268174747
In practice since 2006 (20 years)
NPI: 1982670402 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ip from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ip? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ip

Dr. Michael Ip is an ophthalmology specialist in Pasadena, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ip performed 3,618 Medicare services across 1,730 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ip received a total of $195,993 from 31 pharmaceutical and/or device companies across 186 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ip is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 28% volume in CA $195,993 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,618
Medicare services
Top 28% in CA for ophthalmology
1,730
Unique beneficiaries
$176
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~181 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
962 $33 $372
Aflibercept eye injection (Eylea) 713 $691 $4,165
Extended eye exam with retinal drawing
A detailed examination of the back of the eye that includes creating a drawing of the retina.
696 $20 $119
Eye exam, established patient, focused
A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom.
657 $73 $580
Eye injection for retinal disease
A procedure involving the administration of medication directly into the eye.
384 $95 $905
New patient eye exam, problem focused
A focused examination of the visual system performed during a new patient visit.
108 $73 $570
Retinal photography (fundus photo)
This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures.
57 $31 $455
Ultrasound of eye tissue and structures
A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures.
21 $44 $817
Retinal angiography with dye injection
This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body.
20 $129 $700
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$195,993
Total received (2018-2024)
Avg $27,999/year across 7 years
Top 3% in CA for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
31
Companies
186
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$186,943 (95.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,356 (2.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,693 (1.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$32,936
2023
$20,489
2022
$34,266
2021
$21,362
2020
$5,097
2019
$48,791
2018
$33,052

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Regeneron Pharmaceuticals, Inc.
$10,007
Carl Zeiss Meditec USA, Inc.
$6,195
Apellis Pharmaceuticals, Inc.
$5,002
Boehringer Ingelheim International GmbH
$3,800
Genentech USA, Inc.
$2,750
EyePoint Pharmaceuticals US, Inc.
$1,949
ABBVIE INC.
$1,673
BioCryst Pharmaceuticals, Inc.
$922
Bausch & Lomb Americas Inc.
$386
Ocular Therapeutix, Inc.
$88
Coherus Biosciences Inc.
$68
Astellas Pharma US Inc
$55
LEICA MICROSYSTEMS INC.
$23
Alimera Sciences, Inc.
$19
Top 3 companies account for 64.4% of 2024 payments
All-time payments by company (2018-2024) ›
Regeneron Pharmaceuticals, Inc.
$21,813
ThromboGenics, Inc.
$21,000
Genentech, Inc.
$17,904
Allergan Inc.
$16,623
Hoffmann-La Roche Limited
$15,700
F. Hoffmann-La Roche AG
$11,901
Boehringer Ingelheim Pharmaceuticals, Inc.
$10,050
Novartis Pharma AG
$9,675
Amgen Inc.
$9,286
Apellis Pharmaceuticals, Inc.
$8,669
EyePoint Pharmaceuticals US, Inc.
$6,814
Aerie Pharmaceuticals, Inc.
$6,483
Carl Zeiss Meditec USA, Inc.
$6,195
Novartis Pharmaceuticals Corporation
$5,580
Carl Zeiss Meditec, Inc.
$4,500
Alimera Sciences, Inc.
$4,328
Boehringer Ingelheim International GmbH
$3,800
NOVARTIS PHARMACEUTICALS CORPORATION
$3,500
Genentech USA, Inc.
$2,787
ABBVIE INC.
$2,721
Alcon Vision LLC
$2,446
TISSUETECH, INC.
$1,500
Bausch & Lomb Americas Inc.
$1,034
BioCryst Pharmaceuticals, Inc.
$922
Regeneron Healthcare Solutions, Inc.
$190
Allergan, Inc.
$149
Astellas Pharma US Inc
$143
Ocular Therapeutix, Inc.
$110
Bausch & Lomb, a division of Bausch Health US, LLC
$79
Coherus Biosciences Inc.
$68
LEICA MICROSYSTEMS INC.
$23
Top 3 companies account for 31.0% of all-time payments
Associated products mentioned in payments ›
ARTEVO 800 · BEOVU · BUPARLISIB · CIRRUS HD-OCT · Cimerli · DEXTENZA · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · EYP-1901 · ILUVIEN · Iluvien · Izervay · Jetrea · Lucentis · MIEBO · Non-Covered Product · OZURDEX · PROKERA · Rhopressa · Surgical Microscopes · Syfovre · VABYSMO · VISUDYNE · VYZULTA · Vabysmo · XIPERE · YUTIQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (95%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 3% for ophthalmology in CA.

Looking for an ophthalmology specialist in Pasadena?
Compare ophthalmologists in the Pasadena area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologists nearby

Geographic Context

Ophthalmologists within 10 mi
761
Per 100K population
7.7
County median income
$87,760
Nearest hospital
GLENDALE ADVENTIST MEDICAL CENTER
3.1 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Ip is a mixed practice specialist, with above-average Medicare volume (top 28% in CA), with consulting-driven industry engagement in the top 3% of CA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Ip experienced with retinal imaging (oct scan)?
Based on Medicare claims data, Dr. Ip performed 962 retinal imaging (oct scan) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ip receive payments from pharmaceutical companies?
Yes. Dr. Ip received a total of $195,993 from 31 companies across 186 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ip's costs compare to other ophthalmologists in Pasadena?
Dr. Ip's average Medicare payment per service is $176. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ip) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →